VK-0214

Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, focuses on developing therapies for metabolic and endocrine disorders. Its lead drug, VK2809, targets non-alcoholic steatohepatitis and NAFLD, with other candidates in various clinical trials. The company, headquartered in San Diego, CA, has a market cap of $4.524B.

Viking Therapeutics (VKTX) received a Buy rating from Stifel Nicolaus analyst Annabel Samimy, citing promising advancements in its VK2735 programs. The Phase 2 VENTURE study for oral VK2735 targets obesity with potential for success, while the injectable version is set for Phase 3 trials in 2025. Viking's dual-format strategy enhances market appeal. Morgan Stanley also maintains a Buy rating with a $105 target.

H.C. Wainwright's Joseph Pantginis reiterates a Buy rating on Viking Therapeutics (VKTX) with a $102 target, citing the promising Phase 2 trial of oral VK2735 for weight loss, its competitive edge over rivals like Novo Nordisk, and its potential in the weight-loss drug market.

Viking Therapeutics initiates a Phase 2 trial for VK2735, an oral tablet targeting metabolic disorders, to assess its safety, tolerability, and weight loss efficacy over 13 weeks. The study involves 280 obese or overweight adults, aiming for significant body weight reduction. Previous Phase 1 results showed promising weight loss and safety profiles.

Viking Therapeutics' stock has surged nearly 200% in 2024, raising questions about its valuation compared to other mid-cap biotechs like CRISPR Therapeutics and Axsome Therapeutics. Viking's leading candidate, VK2735, a potential dual GLP-1/GIP weight loss treatment, has shown promising phase 2 results and could generate $21.6 billion in peak sales. Despite risks, Viking's innovative pipeline and potential market impact make it a compelling investment opportunity.

Oral VK2735 showed safety and tolerability over 28 days, with significant weight loss observed. The VENTURE Phase 2 study demonstrated VK2735's efficacy in weight reduction and diabetes status improvement over 13 weeks, supporting potential for less frequent dosing. Viking Therapeutics plans further studies on VK2735 for metabolic disorders.

Viking Therapeutics announced new clinical data for VK2735, showing up to 6.8% placebo-adjusted mean weight loss after 28 days of oral dosing. The VENTURE Phase 2 study demonstrated durable weight loss effects, supporting potential monthly dosing. VK2735 showed encouraging tolerability, with mild GI-related adverse events.